A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
Public ClinicalTrials.gov record NCT05155085. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical treatments. Subjects who complete the randomized, double-blind, placebo-controlled treatment period may have the option to enroll in an open-label extension period and receive up to 7 doses of subcutaneous lirentelimab.
Study identification
- NCT ID
- NCT05155085
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 131 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2022 (Actual)
- Primary completion
- Dec 18, 2023 (Actual)
- Completion
- Apr 17, 2024 (Actual)
- Last update posted
- Oct 15, 2024
2022 – 2024
United States locations
- U.S. sites
- 40
- U.S. states
- 22
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Allakos Investigational Site 218-034 | Birmingham | Alabama | 35209 | — |
| Allakos Investigational Site 218-074 | Cullman | Alabama | 35058 | — |
| Allakos Investigational Site 218-025 | Gilbert | Arizona | 85018 | — |
| Allakos Investigational Site 218-041 | Scottsdale | Arizona | 85258 | — |
| Allakos Investigational Site 218-072 | Canoga Park | California | 91303 | — |
| Allakos Investigational Site 218-056 | Los Angeles | California | 90057 | — |
| Allakos Investigational Site 218-073 | San Diego | California | 92123 | — |
| Allakos Investigational Site 218-051 | San Francisco | California | 94132 | — |
| Allakos Investigational Site 218-013 | Santa Monica | California | 90404 | — |
| Allakos Investigational Site 218-033 | Santa Monica | California | 90404 | — |
| Allakos Investigational Site 218-071 | Colorado Springs | Colorado | 80923 | — |
| Allakos Investigational Site 218-045 | Washington D.C. | District of Columbia | 20037 | — |
| Allakos Investigational Site 218-018 | Doral | Florida | 33172 | — |
| Allakos Investigational Site 218-046 | Greenacres City | Florida | 33467 | — |
| Allakos Investigational Site 218-049 | Jacksonville | Florida | 78758 | — |
| Allakos Investigational Site 218-008 | Miami | Florida | 33134 | — |
| Allakos Investigational Site 218-048 | Sarasota | Florida | 34239 | — |
| Allakos Investigational Site 218-020 | Tampa | Florida | 33607 | — |
| Allakos Investigational Site 218-007 | Tampa | Florida | 33614 | — |
| Allakos Investigational Site 218-068 | Lexington | Kentucky | 40509 | — |
| Allakos Investigational Site 218-055 | Crowley | Louisiana | 70526 | — |
| Allakos Investigational Site 218-012 | Towson | Maryland | 21204 | — |
| Allakos Investigational Site 218-069 | White Marsh | Maryland | 21162 | — |
| Allakos Investigational Site 218-066 | Boston | Massachusetts | 02111 | — |
| Allakos Investigational Site 218-058 | Dilworth | Minnesota | 56529 | — |
| Allakos Investigational Site 218-063 | Missoula | Montana | 59808 | — |
| Allakos Investigational Site 218-032 | Omaha | Nebraska | 68144 | — |
| Allakos Investigational Site 218-026 | Las Vegas | Nevada | 89030 | — |
| Allakos Investigational Site 218-050 | Las Vegas | Nevada | 89119 | — |
| Allakos Investigational Site 218-029 | Great Neck | New York | 11021 | — |
| Allakos Investigational Site 218-053 | Rochester | New York | 14620 | — |
| Allakos Investigational Site 218-001 | Cincinnati | Ohio | 45236 | — |
| Allakos Investigational Site 218-062 | Fairborn | Ohio | 45324 | — |
| Allakos Investigational Site 218-003 | Oklahoma City | Oklahoma | 73118 | — |
| Allakos Investigational Site 218-015 | Oklahoma City | Oklahoma | 73120 | — |
| Allakos Investigational Site 218-061 | Portland | Oregon | 97210 | — |
| Allakos Investigational Site 218-010 | Philadelphia | Pennsylvania | 19103 | — |
| Allakos Investigational Site 218-052 | Dallas | Texas | 75230 | — |
| Allakos Investigational Site 218-047 | Murray | Utah | 84107 | — |
| Allakos Investigational Site 218-009 | Seattle | Washington | 98115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05155085, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05155085 live on ClinicalTrials.gov.